Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis
Authors:
- 1 October 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 67 (7) , 1067-1075
Abstract
Most of the International Prognostic Scoring System (IPSS) high-risk patients with myelodysplastic syndrome partly responded to hypomethylating therapy even with transient remission, while arsenic trioxide (ATO) had partial effect in patients with MDS. Therefore, we sought to investigate the effects and possible mechanisms of the combination of ATO and decitabine (DAC) in MDS cells. In our study, the MUTZ-1 and SKM-1 cells were treated with ATO, DAC or both. Cell viability, cell apoptosis, levels of reactive oxygen species (ROS) and expressions of the endoplasmicreticulum (ER) stress-associated genes and proteins were examined. Results showed the combination of ATO and DAC synergistically inhibited the proliferation and induced apoptosis of MDS cells. Through the RNA-sequence and GSEA gene function analysis, ER stress-related pathway played an important role in apoptosis of MDS cells induced by the combination of ATO and DAC. ER stress-related genes DNA damage inducible transcript 3, GRP78, and activating transcription factor-6 were significantly highly expressed in combination group than those in single agent groups; proteins were confirmed by western blot. The levels of ROS significantly increased in the combination group. Furthermore, the apoptosis of (ATO+DAC) group MDS cells could be partially reversed by antioxidant agent N-acetylcysteine, accompanied by decreased expression of intracellular ROS and ER stress-related genes. These results suggested that the combination of ATO and DAC synergistically induced the apoptosis of MDS cells by increased ROS-related ER stress in MDS cells.Keywords
Funding Information
- Tianjin Municipal Natural Science Foundation youth project
- Scientific Research Project of Tianjin Education Commission
- Tianjin Science and Technology Planning Project
- National Natural Science Foundation of China
This publication has 30 references indexed in Scilit:
- Myelodysplastic syndromes current treatment algorithm 2018Blood Cancer Journal, 2018
- Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM-1 human myelodysplastic syndrome cell lineMolecular Medicine Reports, 2016
- Current Trends in Clinical Studies of Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2015
- Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cellsJournal of Experimental & Clinical Cancer Research, 2014
- Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cellsLeukemia, 2012
- Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic SyndromesSeminars in Oncology, 2011
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapyCancer, 2010
- Decitabine and its role in the treatment of hematopoietic malignanciesLeukemia & Lymphoma, 2007
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004
- Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineBritish Journal of Haematology, 2001